| Literature DB >> 29417182 |
Shahin Mohseni1, John Ivarsson2, Rebecka Ahl3,4, Sinan Dogan2, Sten Saar5, Arvo Reinsoo5, Teesi Sepp5, Karl-Gunnar Isand5, Edvard Garder5, Ilmar Kaur5, Heiti Ruus5, Peep Talving5.
Abstract
INTRODUCTION: The timing and optimal method for common bile duct (CBD) clearance and laparoscopic cholecystectomy remains controversial. Several different approaches are available in clinical practice. The current study presents the experience of two European hospitals of simultaneous laparoscopic cholecystectomy (LC) and intra-operative endoscopic retrograde cholangiopacreatography (IO-ERCP) done by surgeons.Entities:
Keywords: ERCP; Laparoscopic cholecystectomy; One-stage approach
Mesh:
Year: 2018 PMID: 29417182 PMCID: PMC6450829 DOI: 10.1007/s00068-018-0921-z
Source DB: PubMed Journal: Eur J Trauma Emerg Surg ISSN: 1863-9933 Impact factor: 3.693
Fig. 1ERCP with Rendezvous technique: a cholangiography tube in the cystic duct; b cholangiography confirming distal CBD stone (arrow); c cholangiography with guidewire in place; d guidwire in place (Ampulla of Vater); e guidwire caught by endoscopist; f extraction of CBD stones by balloon clearance
Patient demographics, laboratory, preoperative diagnosis and modality for CBD diagnosis
| Total | OUH | NEMC | ||
|---|---|---|---|---|
| Total number of patients, | 201 | 94 | 107 | |
|
| ||||
| Female gender, n (%) | 134 (67%) | 59 (63%) | 75 (70%) | 0.27 |
| Age (mean ± SD) | 55 ± 19 | 51 ± 35 | 58 ± 20 | 0.05 |
| ASA class (median, [LQ, UQ]) | 2 [1, 2] | 2 [1, 2] | N/A | − |
| CCI score (median, [LQ, UQ]) | 2 [1, 4] | 2 [1, 4] | 3 [1, 4] | 0.05 |
|
| ||||
| White blood count, 109/L (mean ± SD) | 9.4 ± 4.1 | 9.6 ± 4.6 | 9.1 ± 3.6 | 0.40 |
| CRP, mg/L (mean ± SD) | 41 ± 71 | 36 ± 72 | 45 ± 70 | 0.40 |
| AST, µkat/L (mean ± SD) | 4.3 ± 3.8 | 5.3 ± 4.2 | 3.4 ± 3.1 | 0.001 |
| ALP, µkat/L (mean ± SD) | 3.5 ± 2.3 | 3.4 ± 2.1 | 3.6 ± 2.5 | 0.52 |
| Bilirubin, µmol/L (mean ± SD) | 54 ± 39 | 51 ± 35 | 56 ± 42 | 0.30 |
| Lipase, µkat/L (mean ± SD) | 14 ± 24 | 16 ± 25 | 10 ± 22 | 0.12 |
|
| ||||
| Cholecystolithiasis, | 93 (46%) | 81 (86%) | 12 (11%) | 0.17 |
| Acute cholecystitis, | 61 (30%) | 36 (38%) | 25 (23%) | < 0.001 |
| Gallstone pancreatitis, | 40 (20%) | 23 (25%) | 17 (16%) | < 0.001 |
| Cholangitis, | 9 (5%) | 5 (5%) | 4 (4%) | 0.74** |
|
| ||||
| Verified CBD stone, | 177 (88%) | 70 (74%) | 107 (98%) | < 0.001 |
| Not verified CBD stone, | 24 (12%) | 24 (26%) | 0 | – |
|
| ||||
| Ultrasound, | 92 (46%) | 16 (17%) | 78 (73%) | |
| MRCP, | 46 (23%) | 46 (49%) | N/A | |
| CT, | 36 (18%) | 7 (7%) | 29 (27%) | |
| CBDS confirmed on IOC, | 94 (47%) | 94(100%) | N/A | |
LQ lower quartile, UQ upper quartile, CCI Charleson’s comorbidity index, CBD common bile duct, MRCP magnetic resonance cholangio-pancreatography, CT computer tomography, IOC intraoperative cholangiography
**Fisher exat test, two sided p value
Outcomes
| Total | OUH | NEMC | ||
|---|---|---|---|---|
| Surgery time, min (mean ± SD) | 105 ± 44 | 120 ± 43 | 91 ± 41 | < 0.001 |
| Iatrogenic pancreatitis, | 6 (3%) | 4 (4%) | 2 (2%) | 0.42* |
| Bile leak, | 2 (1%) | 2 (2%) | 0 (0%) | 0.22* |
| Hospital LOS, days (median, LQ, UQ]) | 4 [3, 7] | 4 [3, 7] | 4 [3, 6] | 0.42 |
| pLOS, days (median, [LQ, UQ]) | 2 [1, 3] | 1.5 [1, 3] | 2 [1, 4] | 0.04 |
LQ lower quartile, UQ upper quartile, LOS length of stay, pLOS postoperative length of stay
*Fisher exat test, two sided p value
Cost for care and procedures at Orebro University Hospital
| Cost (USD) | |
|---|---|
| Total hospital care (mean ± SD) | 9107 ± 3221 |
| Laboratory tests (mean ± SD) | 176 ± 107 |
| Anesthesia (mean ± SD) | 1199 ± 414 |
| Operation (mean ± SD) | 2925 ± 869 |
| ERCP (mean ± SD) | 1550 ± 404 |
| Postop ICU (mean ± SD) | 368 ± 404 |
| Total ward stay (mean ± SD) | 2473 ± 1987 |
| Total ward stay per day (mean ± SD) | 540 ± 126 |
Cost in USD calculated from SEK as of currency rate July 19, 2017 (1 USD = 8.29 SEK)
USD US Dollars, SEK Swedish Crowns, ERCP endoscopic retrograde cholangio-pancreatography, ICU intensive care unit